127 related articles for article (PubMed ID: 3859250)
21. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma.
Arimori S; Nagao T; Shimizu Y; Watanabe K; Komatsuda M
Tokai J Exp Clin Med; 1980 Jan; 5(1):63-71. PubMed ID: 6930119
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals.
Fujimoto S; Tashiro T; Ogawa M
Gan; 1984 Oct; 75(10):937-46. PubMed ID: 6510639
[TBL] [Abstract][Full Text] [Related]
23. Effect of the nitrosourea anti-tumor chemotherapeutical agent MCNU on five human myeloma cell lines.
Otsuki T; Sakaguchi H; Yamada O; Yawata Y; Ueki A
Oncol Rep; 1998; 5(4):827-32. PubMed ID: 9625826
[TBL] [Abstract][Full Text] [Related]
24. Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs.
Kochi M; Takaki S; Kuratsu J; Seto H; Kitamura I; Ushio Y
J Neurooncol; 1994; 19(3):239-44. PubMed ID: 7807174
[TBL] [Abstract][Full Text] [Related]
25. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
26. [Early phase II trial of bestrabucil in hematological malignancies].
Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
[TBL] [Abstract][Full Text] [Related]
27. [Clinical effects of TA-077 in non-Hodgkin's lymphomas].
Kobayashi T; Tanaka I; Nishikawa M; Kita K; Matsuoka N; Miwa H; Saitoh M; Tsukada T; Shirakawa S
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3194-7. PubMed ID: 3777956
[TBL] [Abstract][Full Text] [Related]
28. [Effect of MCNU on brain tumors. Part II: Clinical experience with MCNU on malignant brain tumors].
Wakabayashi T; Yoshida J; Kito A; Inoue I; Kobayashi T; Kageyama N
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2729-37. PubMed ID: 6095764
[TBL] [Abstract][Full Text] [Related]
29. [Effects of K18, a melphalan-human IgG conjugate, on hematologic neoplasms; phase II study experience].
Sakurai M; Maseki N; Hattori M
Gan To Kagaku Ryoho; 1988 May; 15(5):1799-802. PubMed ID: 3163474
[No Abstract] [Full Text] [Related]
30. A phase II study of vindesine in patients with hematological malignancies.
Hulhoven R; Michaux JL; Cornu G; Ferránt A; Bosly A; Delannoy A; Sokal G
Biomedicine; 1980 Apr; 33(2):31-2. PubMed ID: 6931617
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
32. [Effect of intra-arterial and local administration of MCNU on cerebral malignant gliomas].
Watanabe M; Takeda N; Tanaka R
Gan To Kagaku Ryoho; 1995 May; 22(6):811-4. PubMed ID: 7755390
[TBL] [Abstract][Full Text] [Related]
33. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
34. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
35. Combination of vindesine and prednisone in malignant lymphoma and acute leukemia.
Raich PC; Walker BK; Rogers JS; Subramanian VP; Fontana JA; Knost JA; Denning B
Cancer Treat Rep; 1983 May; 67(5):485-7. PubMed ID: 6573959
[TBL] [Abstract][Full Text] [Related]
36. [Phase II study of vindesine in hematological malignancies].
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2509-15. PubMed ID: 6580841
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].
Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973
[TBL] [Abstract][Full Text] [Related]
38. [Phase II study of chlorambucil in patients with hematological malignancies].
Inoue K; Ogawa M; Horikoshi N; Mukaiyama T; Itoh Y; Imajoh K; Ozeki H; Nagamine D; Shinagawa K
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2672-5. PubMed ID: 3307632
[TBL] [Abstract][Full Text] [Related]
39. [Prolonged disappearance of the Ph1 chromosome in a case of chronic myelogenous leukemia after administration of MCNU].
Kobayashi M; Sugiura I; Yamada K
Rinsho Ketsueki; 1987 Sep; 28(9):1640-4. PubMed ID: 3481407
[No Abstract] [Full Text] [Related]
40. An overview of the status of the nitrosoureas in other tumors.
Carter SK
Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
